<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636060</url>
  </required_header>
  <id_info>
    <org_study_id>LowdoseIron</org_study_id>
    <nct_id>NCT04636060</nct_id>
  </id_info>
  <brief_title>Effectiveness of Low-dose Iron Treatment in Non-anaemic Iron-deficient Women</brief_title>
  <official_title>Single Center Clinical Trial to Evaluate the Effectiveness of Low-dose Iron Treatment in Non-anaemic Iron-deficient Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iron deficiency is common in Switzerland and the main reason for anaemia. Nearly one in five&#xD;
      premenopausal women suffers from iron deficiency. Low iron intake, reduced iron resorption or&#xD;
      loss of blood are the main cause for iron deficiency. Symptoms of iron deficiency, for&#xD;
      example fatigue, weakness, headache or exercise intolerance are primarily due to anaemia, but&#xD;
      the same symptoms may also be present in non-anaemic patients with low serum ferritin.&#xD;
      Consequently it is important to detect and treat non-anaemic iron deficiency. Common side&#xD;
      effects of oral iron supplementation are primarily gastrointestinal symptoms like nausea,&#xD;
      vomiting, diarrhea or abdominal pain. There is a positive correlation between appearance of&#xD;
      gastrointestinal symptoms and administered iron dose. To date, only few studies have&#xD;
      investigated effectiveness of low-dose iron supplementation in different target groups. The&#xD;
      aim of this study is to investigate if low dose iron supplementation with 12mg iron per day&#xD;
      for 8 weeks is sufficient to increase serum ferritin levels into a normal range in healthy&#xD;
      premenopausal women suffering from non-anaemic iron deficiency&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase of serum ferritin concentration under iron supplementation</measure>
    <time_frame>8 weeks</time_frame>
    <description>significant increase of serum-ferritin concentration after 8 weeks of low-dose iron-supplementation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side-effects of treatment</measure>
    <time_frame>8 weeks</time_frame>
    <description>Adverse events will be assessed on a report form after 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum hepcidin concentration</measure>
    <time_frame>8 weeks</time_frame>
    <description>no increase in hepcidin-production during low-dose iron supplementation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Iron Deficiency (Without Anemia)</condition>
  <arm_group>
    <arm_group_label>Iron-treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Eisen</intervention_name>
    <description>Treatment with low-dose iron in the form of tablets containing 6mg of iron. Treatment consists of twice-daily oral administration of iron-tablets for 8 weeks in total.</description>
    <arm_group_label>Iron-treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed Consent as documented by signature&#xD;
&#xD;
          -  Female gender&#xD;
&#xD;
          -  Premenopausal&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Regular menstrual cycle&#xD;
&#xD;
          -  BMI in normal range (18-25 kg/m²)&#xD;
&#xD;
          -  Serum-ferritin &lt;30ng/ml&#xD;
&#xD;
          -  No anaemia&#xD;
&#xD;
          -  symptomatic iron deficiency in the past&#xD;
&#xD;
          -  No intake of dietary supplements&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Intake of dietary supplements&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Hypermenorrhea&#xD;
&#xD;
          -  Anaemia&#xD;
&#xD;
          -  Serum-ferritin &gt;30ng/ml&#xD;
&#xD;
          -  BMI &lt;18 kg/m² or &gt;25 kg/m²&#xD;
&#xD;
          -  chronic inflammatory diseases (e.g. colitis)&#xD;
&#xD;
          -  Hypersensitivity to iron-supplements&#xD;
&#xD;
          -  psychiatric disorder&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Alexandre Krayenbühl</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre-Alexandre Krayenbühl</last_name>
    <phone>0041 44 255 1111</phone>
    <phone_ext>1054</phone_ext>
    <email>krayenbuehl@protonmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Pierre-Alexandre Krayenbuehl</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

